|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Merger Mania Besets Japanese Pharmaceuticals
10/19/2005 5:12:49 PM
A law allowing greater foreign investment in Japanese companies is fueling a merger mania in that country's pharmaceutical industry. In April, Astellas Pharma will be created by a merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, which will surpass Takeda Pharmaceutical, currently Japan's largest in terms of sales. This will be followed in October by the just-announced merger of Sankyo, the country's second-largest drug maker, and Daiichi Pharmaceutical, the sixth-largest. A third megamerger between Dainippon Pharmaceutical and Sumitomo Pharmaceutical is also set for October. Driving the mergers is legislation slated to take effect in 2006 that will allow mergers and acquisitions based on share swaps with foreign companies. With drug development costs steep and the government continuously cutting prescription prices, the pharmaceuticals see themselves as vulnerable to a takeover.
Further, Japanese pharmaceuticals believe they need to allocate approximately $955 million for research and development to compete effectively with U.S. pharmaceuticals. Sankyo spends about $860 million, while Daiichi spends almost $573 million. Combined, their total expenditures would exceed the mark, while consolidated revenues would be around $8.7 billion for the year ended in March 2004, superseding the soon-to-be-created Astella's projected $8.1 billion. Takeda had sales of $9.5 billion for the same period.
|
|
|
|
|
|
|
|
|
|
|